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Angiotensinogen gene variation and renoprotective efficacy of
renin-angiotensin system blockade in IgA nephropathy.
Background. Blockade of the renin-angiotensin system
(RAS) is well documented to be renoprotective; however, not
all patients with glomerulonephritis respond well to this ther-
apy. The interindividual variation in response to the RAS block-
ade may be in part genetically determined, whereas the results
have been controversial.
Methods. We investigated whether the therapeutic efficacy
of angiotensin-converting enzyme (ACE) inhibitors and/or an-
giotensin receptor blocker on renal prognosis is modified by the
angiotensinogen gene (AGT) polymorphism in immunoglobulin
A nephropathy (IgAN). In total, 259 patients with histologically
proven IgAN were analyzed for clinical manifestations, renal
survival, and their associations with AGT A(20)C and M235T.
Results. The renal prognosis of 110 patients, who received
ACE inhibitors/angiotensin receptor blocker during their clini-
cal course, was significantly better than those without ACE
inhibitors/angiotensin receptor blockers despite higher blood
pressures and heavier proteinuria. The Cox proportional haz-
ards regression model showed an increased hazard ratio (HR)
for urinary protein (more than 1.0 g/day) of 3.346 (P 0.0001),
hypertension of 1.949 (P  0.01), deteriorated renal function
of 3.040 (P  0.0001), no ACE inhibitor/angiotensin receptor
blocker administration of 2.725 (P  0.0004), and the T235
and C(20) haplotype of 1.608 (P  0.0322). Only in patients
carrying at least one M235 and A(20) haplotype did the
administration of ACE inhibitors/angiotensin receptor block-
ers have no significant effect on the prognosis of renal function
(Kaplan-Meier, log rank test, 2  0.700; P  0.4028), whereas
it was significant in patients who had other haplotypes of AGT
(2  11.805; P  0.0006).
Conclusion. This study provides evidence that the M235T
and A(20)C genotype of AGT can influence the therapeutic
efficacy of a RAS blockade on the renal survival in IgAN.
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Immunoglobulin A nephropathy (IgAN), character-
ized by mesangial proliferative glomerulonephritis with
predominant deposits of IgA1 in the mesangium, is the
most prevalent form of glomerulonephritis and a major
cause of end-stage renal disease (ESRD) in the world [1].
It has been reported that 9% to 50% patients with IgAN
progress to ESRD within 20 years of disease onset, al-
though the disease has a variable clinical course [2–4].
The mechanisms of the interindividual variation in the
rate of disease progression remain to be elucidated, but
it has been proposed that several genetic backgrounds
are associated with the disease progression in IgAN [5, 6].
It has been well documented that increased production
or activity of angiotensin II plays a detrimental role in
the glomerular response to injury. Recently, both angio-
tensin-converting enzyme (ACE) inhibitor and angioten-
sin II receptor blocker therapies have been shown to
decrease the proteinuria by improving glomerular perm-
selectivity in IgAN [7, 8], although about half of the
patients did not respond to the ACE inhibitor/angioten-
sin receptor blocker treatment [9].
The interindividual variation in response to the renin-
angiotensin system (RAS) blockade may partly be genet-
ically determined. It has been suggested that genetic
backgrounds, which have an association with the local
tissue activity of RAS in diseased kidney, may also deter-
mine the responsiveness to ACE inhibitor/angiotensin
receptor blocker. The candidate gene variant proposed
to date is an insertion/deletion (I/D) polymorphism in
the angiotensin-converting enzyme gene (ACE), which
has been shown to influence the concentration of ACE
both in circulation and local tissue [10, 11]. However,
the results from previous studies on the association be-
tween the ACE I/D polymorphism and the respon-
siveness to ACE inhibitor therapy are conflicting [12–16].
Another important gene variant, which has been proved
to affect the activity of the RAS, is polymorphisms in
the angiotensinogen gene (AGT, MIM 106150), although
so far little information is available on its possible associ-
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ation with the responsiveness to ACE inhibitor/angio-
tensin receptor blocker therapy. However, accumulating
evidence indicates that AGT M235T variant is important
in the pathogenesis of cardiovascular diseases such as
hypertension. It has been suggested that changes in the
5 upstream core promotor region of AGT, which is essen-
tial for the transcription of angiotensinogen mRNA, causes
a functional alteration, which may contribute to the patho-
genesis of cardiovascular diseases [17]. An adenine-to-
cytosine transition at nucleotide –20 of the core promo-
tor region [A(20)C] has been shown to increase basal
promotor activity of AGT by increasing the affinity of
adenoviral major late transcription factor (MLTF) to
this region of the promotor [18].
In this study, we investigated the possible interaction
of AGT A(20)C and M235T polymorphisms with the
renoprotective efficacy of the RAS blockade on renal
survival in patients with IgAN.
METHODS
Study population
The protocol of the present study was approved by the
ethics committee of the institution involved. Japanese
patients were eligible for inclusion in the analysis when
(1) they had been diagnosed as having IgAN by kidney
biopsy at our institute between 1976 and 2000; (2) they
had no evidence of systemic diseases such as hepatic
glomerulosclerosis, Scho¨nlein-Henoch purpura, and rheu-
matoid arthritis; (3) they had been followed up for at
least 12 months in our institute; and (4) written informed
consent for genetic study was obtained. Patients who
received immunosuppression therapy other than cortico-
steroids were excluded from the analysis. In general, kid-
ney biopsy was indicated for patients with persistent pro-
teinuria and hematuria sustained for at least 6 months,
those with nephrotic range proteinuria, and those with
reduced renal function.
In total, 259 IgAN patients were recruited for this
study. In all cases, the diagnosis of IgAN was based on
a kidney biopsy that revealed the presence of dominant
or codominant glomerular mesangial deposits of IgA as
assessed by immunofluorescence examination.
Baseline clinical data and survival analysis
Clinical characteristics of the patients before the start
of any treatment, including age, gender, office blood pres-
sure, level of urinary protein excretion (g/day), serum
creatinine (mg/dL), and 24-hour creatinine clearance
(mL/min/1.73 m2 body surface area), were retrospectively
reviewed from their medical records. Hypertension was
defined by the use of one or more antihypertensive medi-
cations and/or a blood pressure greater than or equal to
140 mm Hg systolic or 90 mm Hg diastolic. The patients
were followed up for the mean duration of 92.2  67.7
(mean  SD) months. In the survival analysis, the pri-
mary end point (progressive renal disease) was defined
as the date at which the serum creatinine level was double
that of the time at diagnosis, or when the patient underwent
their first hemodialysis. All patients were treated according
to a standardized procedure of our institute. Corticoste-
roids were administered to patients with a urinary protein
excretion of more than 1.0 g/day at the time of renal biopsy
with the exception of cases with deteriorated renal function
(creatinine clearance30 mL/min) and those over 65 years
old. Patients with contraindication to steroid treatment,
such as infectious diseases, glaucoma, refractory peptic
ulcer, and severe osteoporosis, were also excluded from
glucocorticoid therapy as judged by the physicians. An
additional exception was a case in which no informed
consent for corticosteroid therapy was available. Out of
the 259 patients, 71 (27.4%) received corticosteroids,
whereas 90 patients (34.7%) had a proteinuria of more
than 1.0 g/day at the time of diagnosis. Antihypertensive
agents were used in combination with or without ACE
inhibitors/angiotensin receptor blocker to maintain the
blood pressure lower than 140 mm Hg systolic and 90
mm Hg diastolic. The administration of glucocorticoids,
antihypertensive agents, and ACE inhibitors/angiotensin
receptor blockers was also recorded for each patient.
In total, 110 patients received ACE inhibitors and/or
angiotensin receptor blockers as antihypertensive agents
after the diagnosis and during their clinical course. About
half of the ACE inhibitors prescribed was enalapril
(2.510 mg/day) in 56 patients, while others included
temocapril (14 mg/day) in 18 patients, quinapril (510
mg/day) in 15 patients, lisinopril (510 mg/day) in seven
patients, captopril (2537.5 mg/day) in four patients,
and delapril (7.530 mg/day) in three patients patients.
Angiotensin receptor blockers were prescribed in 33 pa-
tients (2550 mg/day of losartan in 16 patients, 28 mg/
day of candesartan in 17 patients). Only 26 patients were
administered both ACE inhibitors and angiotensin recep-
tor blockers. Of 26 patients, 21 patients received ACE
inhibitors and angiotensin receptor blockers simultane-
ously and five did so sequentially (ACE inhibitors to
angiotensin receptor blocker). Since the choice of antihy-
pertensive agents was not controlled but was left to the
decision of each physician, there was a tendency for ACE
inhibitors/angiotensin receptor blockers to be preferably
administered to patients with a high-grade proteinuria
(Table 2).
Determination of the AGT genotype
Genomic DNA from the peripheral blood cells of 259
Japanese patients with histologically confirmed IgAN
was isolated by an automatic DNA isolation system (NA-
1000, Kurabo, Osaka, Japan). The M235T variant of
AGT at exon 2 was determined as described previously
[19]. To determine the A to C transition at nucleotide
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Table 1. The genotype distributions, allele frequencies, and
estimated haplotype frequencies of AGT polymorphisms
A(20)C M235T
Genotype AA 160 MM 3
AC 85 MT 87
CC 14 TT 169
Total 259 259
Allele A 0.782 M 0.180
C 0.218 T 0.820
Haplotype T235 and C(20) 0.2182
T235 and A(20) 0.6023
M235 and A(20) 0.1795
20 in the 5 upstream region of the core promoter in
the AGT gene, the following primers were used: 5
primer, 5-AGAGGTCCCAGCGTGAGTGTC-3 (nu-
cleotides –166 to –144); 3 primer, 5-AGCCCACAGC
TCAGTTACATC-3 (nucleotides 81 to 101) [20]. Poly-
merase chain reaction (PCR) was performed in a final
volume of 50L containing 100 ng DNA, 10 pmol of each
primer, 250 mmol/L of each of the four desoxynucleoside
triphosphates (dNTPs), 1.5 mmol/L MgCl2, 50 mmol/L
KCl, 10 mmol Tris-HCl at pH 8.4, and 2 U of Taq poly-
merase (Takara, Shiga, Japan). The PCR conditions
were as follows: 30 cycles of 94C for 30 seconds, 64C
for 1 minute, and 72C for 1 minute. After PCR, 265 bp
products, including the 5 upstream core promoter re-
gion, were obtained. Next, 8.5 L of unpurified product
was digested with 2 U of EcoO109I (Takara) for at least
3 hours at 37C. These samples were separated by 3%
agarose gel electrophoresis, and visualized by ethidium
bromide staining.
Statistical analysis
Statview 5.0 statistical software (Abacus Concepts,
Inc., Berkeley CA, USA) was used for statistical analysis.
Continuous variables were compared using the Mann-
Whitney U-test. Chi-square analysis was used when com-
paring allele frequencies and categoric variables between
the groups. Hardy-Weinberg equilibrium was tested by
a chi-square test with 1 df. The Kaplan-Meier method
and Cox proportional hazards regression model were
used to analyze the time course from renal biopsy to
end point. In the Cox regression model, we first tested
each variable by univariate analysis, including age, gen-
der, body mass index, urinary protein, hypertension, de-
teriorated renal function at the time of diagnosis, steroid
therapy, and administration of ACE inhibitors/angioten-
sin receptor blockers, as well as the gene polymorphisms.
Deteriorated renal function was defined as a serum creat-
inine level of more than 1.2 mg/dL or creatinine clear-
ance of less than 70 mL/min/1.73 m2 body surface area.
The covariates, which were statistically significant in the
univariate analysis, were then included in the multivari-
ate analysis. The effects of these covariates were ex-
pressed by a hazard ratio (HR). A value of P  0.05 was
considered to indicate statistical significance. Haplotype
analysis, based on a maximum likelihood method, was
performed using ARLEQUIN software Version 2.0 (Ge-
netics and Biometry Laboratory, Department of Anthro-
pology, University of Geneva, Geneva, Switzerland).
Pairwise linkage disequilibrium coefficients were calcu-
lated and expressed as the D  D/D max or D/D min,
according to Thompson et al [21].
RESULTS
Genotype distribution, allele frequency, and estimated
haplotype frequency of the AGT gene variant
Table 1 summarizes the results of genotyping for the
AGT polymorphisms of A(20)C and M235T in this
study. The expected frequencies of the genotypes, as-
sumed to be under the Hardy-Weinberg equilibrium,
were no different from the observed genotype distribu-
tion. The genotype and allele frequencies of AGT
A(20)C and M235T were consistent with those of pre-
vious reports for the Japanese population [22, 23]. The
estimated frequencies of the haplotypes are also shown
in Table 1. The haplotype analysis revealed that the two
alleles were in a tight linkage disequilibruim with the
linkage disequilibrium coefficient (D) of 1.000 (P 
0.0001). Only three haplotypes: T235 and C(20); T235
and A(20); and M235 and A(20), were observed,
indicating that the polymorphism at –20 of AGT only
existed in a subset of the 235T alleles (Table 1).
Characteristics of the patients and comparisons
between patients who did or did not receive ACE
inhibitors/angiotensin receptor blockers
Table 2 shows the clinical manifestations of the pa-
tients both at the baseline and during the observation.
Out of 259 patients 110 (42.5%) received ACE inhibi-
tors/angiotensin receptor blockers after the diagnosis
and during their clinical course. Comparisons were made
between patients who did or did not receive ACE inhibi-
tor/angiotensin receptor blocker therapy. At baseline,
there was no difference in gender, serum creatinine, or
creatinine clearance. However, the patients who received
the ACE inhibitor/angiotensin receptor blocker therapy
were found to be older, have heavier urinary protein,
and higher blood pressures than compared with those
who did not. During the mean observation period of 92.2
67.7 months, 30.5% (79) of patients progressed to pro-
gressive renal disease. Despite the obvious clinical risk
factors at the baseline such as heavier proteinuria and
higher blood pressure, the incidence of progressive renal
disease was significantly lower in patients with the ACE
inhibitor/angiotensin receptor blocker administration (2
15.786, P  0.0001). As a consequence of the higher level
of proteinuria, a higher proportion of patients with ACE
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Table 2. Clinical characteristics of patients with immunoglobulin A nephropathy (IgAN) and comparisons between patients who did or did
not receive angiotensin-converting enzyme inhibitor/angiotensin receptor blockade (ACEI/ARB)
ACEI/ARB administration
Total Received Not received
N  259 N  110 N  149 P value 2
At the time of renal biopsy
Age year 37.013.4 39.113.8 35.513.0 0.0492
Gender male % 46.3 49.1 44.3 0.4442 0.585
Urinary protein excretion g/day 1.311.31 1.441.21 1.211.39 0.0231
Serum creatinine mg/dL 1.000.63 0.920.32 1.060.78 0.6138
Creatinine clearance mL/min 88.833.0 90.730.1 87.335.0 0.3437
Blood pressure mm Hg
Systolic 127.618.2 130.617.8 125.218.3 0.0135
Diastolic 77.313.3 78.913.5 76.013.1 0.1021
Incidence of hypertension % 35.6 44.0 29.2 0.0144 5.986
During observation
Observed period month 92.267.7 91.774.9 92.662.2 0.3238
Incidence of progressive renal disease % 30.5 17.3 40.3 0.0001 15.786
Corticosteroid % 27.5 39.0 18.8 0.0005 12.192
ACEI/ARB % 42.5 100 0
Blood pressure mm Hg
Systolic 128.416.6 130.015.6 127.217.3 0.0749
Diastolic 77.511.6 78.310.6 76.912.4 0.2524
Values are meanSD.
Table 3. Cox proportional hazard model to test the significance of
clinical covariates and genotypes of AGT polymorphisms as
predictors of renal survival
Variable P value HR 95% CI
Urinary protein excretion 	1.0 g/day 0.0001 3.346 1.817, 6.162
Hypertension 0.0100 1.949 1.173, 3.238
Deteriorated renal function 0.0001 3.040 1.795, 5.155
No ACEI/ARB administration 0.0004 2.725 1.561, 4.755
T235 and C(20) haplotype of AGT 0.0322 1.608 1.074, 3.039
Abbreviations are: HR, hazard ratio; deteriorated renal function, a serum
creatinine level of more than 1.2 mg/dL or creatinine clearance of less than
70 mL/min/1.73 m2 body surface area at the time of diagnosis; ACEI/ARB,
angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker;
CI, confidence interval.
inhibitor/angiotensin receptor blocker therapy were
treated with glucocorticoids. The mean blood pressure
during the clinical course was no different between the
two groups.
Identification of risk factors for the progression to
progressive renal disease
Cox proportional hazards regression analysis was used
to test the significance of the clinical covariates at the
time of diagnosis and the genotypes of the AGT poly-
morphism. In the multivariate analysis, a urinary protein
excretion of more than 1.0 g/day, hypertension, deterio-
rated renal function, no ACE inhibitor/angiotensin re-
ceptor blocker administration, and the T235 and C(20)
haplotype of AGT were identified as significant and inde-
pendent risk factors (Table 3), whereas steroid therapy,
age, and gender were not. The T235 and C(20) haplo-
type of AGT was demonstrated to be a independent risk
factor for progressive renal disease with an increased
HR of 1.608 (95% CI, 1.074 to 3.039; P  0.0322) even
after adjusting for the other significant covariates, includ-
ing a urinary protein of more than 1.0 g/day (HR, 3.346;
95% CI, 1.817 to 6.162; P  0.0001), hypertension (HR,
1.949; 95% CI, 1.173 to 3.238; P  0.0100), deteriorated
renal function at the time of renal biopsy (HR, 3.040;
95% CI, 1.795 to 5.155; P  0.0001), and no administra-
tion of ACE inhibitors/angiotensin receptor blockers
(HR, 2.725; 95% CI, 1.561 to 4.755; P  0.0004). In the
univariate analysis, the M235 and A(20) haplotype was
not a significant prognostic factor (HR, 0.776; 95% CI,
0.477 to 1.261; P  0.3055). The therapeutic efficacy
of ACE inhibitors/angiotensin receptor blockers on the
renal survival was confirmed by Kaplan-Meier analysis
(Fig. 1A). The mean survival of renal function in patients,
who received ACE inhibitors/angiotensin receptor block-
ers, was significantly longer than that of those without
ACE inhibitors/angiotensin receptor blockers (198 
11.6 months vs. 139.0  6.8 months, respectively; log
rank test 2  10.728, P  0.0011). Figure 1B shows the
renal survival within a subgroup of patients who received
steroid therapy (N 71) with or without ACE inhibitors/
angiotensin receptor blockers, as well as those with ACE
inhibitor/angiotensin receptor blocker therapy but no
steroids (N  67). The therapeutic efficacy was clearly
seen within the group with steroid therapy (Kaplan-
Meier log rank test, 2  10.032; P  0.0015), indicating
that the renoprotective effect of ACE inhibitors/angio-
tensin receptor blockers was independent of steroid
treatment. In addition, the renal survival of patients with
ACE inhibitors/angiotensin receptor blockers but no ste-
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Fig. 1. Renal survival rate in the total 259 im-
munoglobulin A nephropathy (IgAN) patients,
and in 71 cases, which were treated with cortico-
steroids, as well as those with ACE inhibitors/
angiotensin receptor blockers (ACEI/ARB)
but no steroids. (A ) In the total 259 patients,
the renal survival of patients, who received
ACE inhibitors/angiotensin receptor blockers
(N  110) was significantly better than that
in those who did not (N  149; Kaplan-Meier
log rank test; 2  10.728, P  0.0011). (B )
In the patients, who received corticosteroids,
the renal survival of patients, who received
ACE inhibitors/angiotensin receptor blockers
(N  43) was significantly better than that in
those who did not (N  28; 2  10.032, P 
0.0015). The renal survival of patients with
ACE inhibitors/angiotensin receptor blockers
but no steroids (N 67) was no different from
that of those with both ACE inhibitors/angio-
tensin receptor blockers and steroids (2 
0.235; P 0.6277), but was significantly better
than that of those with steroids but no ACE
inhibitors/angiotensin receptor blockers (2 
11.519; P  0.0007). PRD is progressive renal
disease.
Table 4. Cox proportional hazard model to test the significance of clinical covariates on patients with or without the T235 and C(20)
haplotype of AGT
Patients with T235 and C(20) (N  99) Patients without T235 and C(20) (N 160)
Variable P value HR 95% CI P value HR 95% CI
Urinary protein excretion 	1.0 g/day 0.0010 4.263 1.792, 10.139 0.0048 1.981 1.082, 8.029
Hypertension 0.0268 1.974 1.122, 6.141 0.0085 2.538 1.268, 5.079
Deteriorated renal function 0.0010 1.351 1.098, 2.364 0.0001 8.197 3.759, 17.857
No ACEI/ARB administration 0.0069 1.952 1.208, 5.368 0.0012 3.620 1.663, 7.880
Abbreviations are: HR, hazard ratio; deteriorated renal function, a serum creatinine level of more than 1.2 mg/dL or creatinine clearance of less than 70 mL/min/
1.73 m2 body surface area at the time of diagnosis; ACEI/ARB, angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker; CI, confidence interval.
roids was no different from that of those with both ACE
inhibitors/angiotensin receptor blockers and steroids
(2  0.235; P  0.6277), but was significantly better
than that of those with steroid but no ACE inhibitors/
angiotensin receptor blockers (2  11.519; P  0.0007).
Renoprotective efficacy of ACE inhibitor/angiotensin
receptor blocker therapy and the AGT haplotype
Next to examine whether the AGT polymorphism af-
fects the renoprotective effect of ACE inhibitors/angio-
tensin receptor blockers, the Cox proportional hazards
analysis was performed on patients with or without the
T235 and C(20) haplotype (Table 4), and on those with
or without M235 and A(20) haplotype (Table 5). The
therapeutic efficacy was significant both in patients with
and without the T235 and C(20). On the other hand,
the HR of no ACE inhibitor/angiotensin receptor blocker
administration was 1.092 (95% CI, 0.661 to 3.418; P 
0.4701) in the patients carrying the M235 and A(20)
haplotype of AGT, whereas it was significant in those
with other haplotypes (HR, 2.715; 95% CI, 1.417 to 5.202;
P  0.0026). Figure 2 shows a comparison of the renal
survival rates in patients with or without ACE inhibitor/
angiotensin receptor blocker administration, who did
(Fig. 2A) and did not carry (Fig. 2B) the M235 and
A(20) haplotype of AGT, respectively. Again, within
a subgroup of patients with at least one haplotype of
M235 and A(20) (N 90), the renal survival rate was no
different between groups with or without ACE inhibitor/
angiotensin receptor blocker treatment (Kaplan-Meier
log rank test, 2  0.700, P  0.4028). In contrast, a
remarkable therapeutic efficacy on the renal survival
rate was observed in the patients lacking the M235 and
A(20) haplotype (N  169; Kaplan-Meier log rank
test, 2 11.805, P 0.0006). Table 6 shows the compari-
sons of clinical characteristics between groups of patients
with and without the M235 and A(20) haplotype. No
significant difference was observed in any point between
the two groups. The blood pressures both at baseline
and during the observation as well as the incidence of
hypertension were numerically higher in the patients
without M235 and A(20), although the differences were
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Table 5. Cox proportional hazard model to test the significance of clinical covariates on patients with or without the M235 and A(20)
haplotype of AGT
Patients with M235 and A(20) (N  90) Patients without M235 and A(20) (N 169)
Variable P value HR 95% CI P value HR 95% CI
Urinary protein excretion 	1.0 g/day 0.0418 3.255 1.045, 10.143 0.0032 2.763 1.407, 5.426
Hypertension 0.0113 2.214 1.329, 5.914 0.0288 1.930 1.070, 3.480
Deteriorated renal function 0.0054 4.032 1.511, 10.753 0.0013 2.747 1.484, 5.076
No ACEI/ARB administration 0.4701 1.092 0.661, 3.418 0.0026 2.715 1.417, 5.202
Abbreviations are: HR, hazard ratio; deteriorated renal function, a serum creatinine level of more than 1.2 mg/dL or creatinine clearance of less than 70 mL/min/
1.73 m2 body surface area at the time of diagnosis; ACEI/ARB, angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker; CI, confidence interval.
Fig. 2. Renal survival rate in patients with (N
90), and without the M235 and A(20) haplo-
type (N  169). (A) In patients with the haplo-
type M235 and A(20), the renal survival of
patients, who received ACE inhibitors/angio-
tensin receptor blockers (ACEI/ARB) (N 40)
was not significantly different from that in those
who did not (N  50; Kaplan-Meier log rank
test; 2  0.700, P  0.4028). (B) In contrast,
in the patients without the M235 and A(20)
haplotype, the renal survival of patients, who
received ACE inhibitors/angiotensin receptor
blockers (N  70) was significantly better than
that in those who did not (N  99; 2  11.805,
P  0.0006). PRD is progressive renal disease.
Table 6. Comparisons of clinical characteristics between patients with and without the M235 and A(20) haplotype of the AGT polymorphism
With M235 and A(20) Without M235 and A(20)
(N  90) (N  169) P value 2
At the time of renal biopsy
Age year 37.613.7 36.713.3 0.5688
Gender male % 40.0 49.7 0.1359 2.224
Urinary protein excretion g/day 1.241.38 1.351.27 0.5220
Serum creatinine mg/dL 0.960.42 1.020.72 0.7332
Creatinine clearance mL/min 90.036.1 88.131.3 0.8980
Blood pressure mm Hg
Systolic 125.516.3 128.719.2 0.1712
Diastolic 76.413.3 77.813.4 0.3202
Incidence of hypertension % 27.6 39.8 0.0522 3.691
During the observation
Observed period month 92.171.2 92.266.0 0.7413
Incidence of progressive renal disease % 25.6 33.1 0.2070 1.592
Glucocorticoid % 24.7 29.1 0.4634 0.538
ACEI/ARB % 44.4 41.4 0.6392 0.220
Dosage of enarapril mg (N  56) 4.62.1 18) 4.51.9 38) 0.9013(N  (N 
Duration of enarapril months (N  56) 82.658.1 84.966.3 0.8579
Blood pressure mm Hg
Systolic 125.214.8 126.817.2 0.2410
Diastolic 75.811.1 78.511.8 0.1761
ACEI/ARB is angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker. Values are meanSD.
not statistically significant. In patients who received enal-
april (N 56), the average dosage of drug and the admin-
istration duration were no different between patients
with or without the M235 and A(20) haplotype.
DISCUSSION
A characteristic of the present study was that the reno-
protective efficacy of ACE inhibitors/angiotensin recep-
tor blockers on the prognosis of renal function, but not
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on proteinuria over a short-term period, in IgAN was
evaluated by a sufficiently long-term observation, and
its association with AGT gene polymorphism was ana-
lyzed by multivariate and time-to-event analysis. The
therapeutic efficacy was independent of other clinical
variables such as proteinuria, hypertension, deteriorated
renal function at the baseline, and steroid therapy. The
important and interesting finding in the present study is
that a subgroup of patients, who carry at least one M235
and A(20) haplotype of AGT, did not respond well to
the ACE inhibitor/angiotensin receptor blocker therapy,
whereas the treatment was remarkably effective in pa-
tients without this haplotype. The antiproteinuric effect
of ACE inhibitors/angiotensin receptor blockers may be
associated with the effect on renal survival. However,
accurate assessment of the quantitative antiproteinuric
effect over a long-term period was difficult in this retro-
spective style study, because consistent measurements
of urinary protein excretion were not always available
for each subject. In fact, even within patients who had
stable renal functions over a long period, we sometimes
observed fluctuations in the urinary protein excretion of
up to 50% or more. Therefore, in this study the renopro-
tective effect was evaluated by long-term renal survival,
which would have more important clinical implications.
It is important to predict the renoprotective effects of
antihypertensive agents in individual patients with renal
disease. It has been reported that polymorphism in the
ACE gene is associated with the therapeutic efficacy of
ACE inhibitors on proteinuria over a relatively short-
term observation period in IgAN and diabetic nephropa-
thy, whereas the results from previous studies are con-
flicting [12–16]. In addition to the possible reasons for
the conflicting conclusions, which include differences in
the ethnicity, study design and relatively small sample
sizes, there is the possibility that the contribution of the
ACE I/D polymorphism is of insufficient magnitude to
lead to any obvious or definite conclusion from the differ-
ent study designs in various ethnic populations.
Genetic variations in AGT have been shown to be
associated with variations in plasma angiotensinogen lev-
els. The M235T polymorphism, which is in a complete
linkage disequilibrium with the A(6)G polymorphism
of the AGT, is associated with an increased risk of essen-
tial hypertension in multiple populations [24, 25]. In ad-
dition, association of AGT A(20)C with essential hy-
pertension in the Japanese population has been reported
[20, 26, 27]. Recently, we provided evidence that both
the M235T and A(20)C polymorphisms in AGT were
associated with the progression of renal dysfunction in
137 patients with IgAN, whose renal function was pre-
served at the time of renal biopsy [28]. Our present
result, that the T235 and C(20) haplotype is an inde-
pendent risk factor for progressive renal disease in all
patients with IgAN, which included those with deterio-
rated renal function at baseline, is consistent with both
our previous study and a previous report in the Cauca-
sian population [29]. The prognostic significance of the
T235 and C(20) haplotype observed in this study was
relatively weak in comparison with that of our previous
result. This may partly be a consequence of an associa-
tion between T235 and C(20) and progression of renal
dysfunction because deteriorated renal function at the
baseline, which was excluded from the previous analysis,
was included as a covariate in the Cox proportional haz-
ard model in the present study. Although there was no
significant difference in blood pressures between groups
with each AGT haplotype in our patients with IgAN,
we cannot provide any evidence to support or deny the
possible association between the AGT polymorphisms
and hypertension from the results of this study because
a substantial proportion of the study population had
renal dysfunction, which is likely to be the cause of hyper-
tension and may affect the plasma AGT level.
Although we could not provide data on the circulating
and/or local tissue activity of angiotensin II in each geno-
type, both T235 and C(20) alleles of AGT have been
found to be functionally associated with higher transcrip-
tional activity of the gene [22, 30]. Therefore, it is likely
that the more rapid progression of renal dysfunction in
patients carrying the haplotype T235 and C(20) is due
to the higher activity of angiotensin II than those without
this haplotype. Conversely, it is not surprising that pa-
tients carrying the M235 and A(20) haplotype, who
are assumed to have lower transcriptional activity of
AGT, would be resistant to the efficacy of the RAS
blockade because of their lower angiotensin II activity
in tissues.
There is a possibility that the group with M235 and
A(20) received lower doses of ACE inhibitors/angio-
tensin receptor blockers than the other group, although
in some of patients the average dose and duration of
enalapril administration were no different because their
blood pressures tended to be, but not significantly, lower
at the baseline. This may explain in part the apparent
lack of efficacy of ACE inhibitors/angiotensin receptor
blockers in the group with M235 and A(20).
To elucidate the precise molecular mechanism of the
finding in this study, the local tissue activity of angioten-
sin II in the kidney and its response to the ACE inhibitor/
angiotensin receptor blocker administration in patients
with each set of AGT haplotype needs to be investigated
by a randomized controlled prospective study. Studies
in other ethnic populations are also needed because
there are substantial differences in the haplotype fre-
quencies of AGT between Caucasian and Japanese pop-
ulations [23]. It is known that single nucleotide polymor-
phisms with high allele frequencies are more statistically
informative than those with low allele frequencies in
association studies [31].
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This study was not a randomized controlled study and,
in fact, the ACE inhibitors/angiotensin receptor blockers
were preferably prescribed to patients with a heavier
proteinuria and higher blood pressure at the time of
diagnosis, both of which were independent clinical risk
factors for the progression of renal dysfunction. How-
ever, the remarkable renoprotective effect of the ACE
inhibitor/angiotensin receptor blocker therapy was ob-
served in this study. Despite more severe clinical mani-
festations at baseline, the renal outcome was significantly
better in the patients who received ACE inhibitor/angio-
tensin receptor blocker treatment than that in those who
did not. To confirm the results of the present study, a
randomized controlled prospective study with a large-
scale population of patients is necessary. However, mak-
ing conclusions about the long-term renal survival of
IgAN in a prospective study is difficult, because the ac-
tual prognosis of renal function in each case can only be
determined after a sufficiently long observation period.
In fact, a substantial proportion of our patients had stable
renal function and only one third of them progressed to
the end point during the mean observation period of
92.2 months. Therefore, we believe that the Cox hazard
regression analysis, and time-to-event analysis, using past
precise medical records, is an adequate and feasible
method to investigate the long-term renal prognosis.
Moreover, with this approach, no assumption of linearity
was necessary and information could be drawn from
patients with a partial follow-up. Therefore, even if the
bias as a result of this being a retrospective study is taken
into account, this study provides a new theory suggesting
that the interindividual variation in responsiveness to the
RAS blockade is associated with AGT polymorphism.
ACE inhibitors are well established as renoprotective
drugs both in diabetic and nondiabetic renal disease
[8, 32]. Angiotensin receptor blockers are the other in-
hibitors of the RAS, although it has distinct pharmaco-
logic properties from ACE inhibitors. At present we
have no knowledge or data on comparisons of the long-
term renoprotective effect of either ACE inhibitors or
angiotensin receptor blockers alone, with a combination
of both drugs [8], but similar renal vasodilation by both
classes of drugs has been reported in studies on direct
comparisons of renal hemodynamic effects in patients
with hypertension or renal diseases [33, 34]. The combi-
nation of ACE inhibitors and angiotensin receptor
blockers has been reported to be at least additive in
decreasing protein excretion in patients with IgAN
[35, 36], whereas the results of larger trials are still con-
troversial [37, 38]. In the present study, the numbers of
subjects who were treated with each drug were not large
enough to analyze separately. Further investigation using
a fixed medication protocol is also needed on this matter.
CONCLUSION
This study provides the first evidence that AGT poly-
morphisms can influence, not only the prognosis of renal
function, but also the renoprotective efficacy of a RAS
blockade on the long-term renal survival in IgAN pa-
tients. Although further studies in other ethnic popula-
tions and investigations on the association of the AGT
haplotypes with local tissue activity of angiotensin II are
necessary, the results of this study, if confirmed, suggest
that more active ACE inhibitor/angiotensin receptor
blocker usage may be applied for patients with no M235
and A(20) haplotype of AGT even in an early phase
of the disease. Further work needs to be undertaken
to assess whether patients with the M235 and A(20)
haplotype can responding some way to the RAS block-
ade or to other classes of antihypertensive agents.
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